Morphea (localized scleroderma)

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Morphea is a fibrosing disorder of the skin without systemic involvement. It can be clinically classified in different forms: circumscribed, linear, generalized, pansclerotic and mixed forms. The pathogenesis is not completely understood. An underlying predisposition and environmental factors are required to develop the disease. No causal treatment for morphea exists. Topical systemic and phototherapy are used. Topical treatments are adequate for limited forms, while phototherapy and systemic treatment are used for the more severe forms of the disease. Corticosteroids are the mainstay of topical treatments. Topical calcipotriol and tacrolimus have been evaluated in open studies and they seem to improve significantly morphea. UVA1 which penetrate deeper in the dermis than narrow-band UVB are usually considered the best option in phototherapy. Methotrexate is the systemic drug which has the best evidences; it can be used in addition to corticosteroids, in particular in severe morphea of young people.

Original languageEnglish
Title of host publicationEuropean Handbook of Dermatological Treatments, Third Edition
PublisherSpringer Berlin Heidelberg
Pages637-642
Number of pages6
ISBN (Print)9783662451397, 9783662451380
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Localized Scleroderma
Phototherapy
Adrenal Cortex Hormones
Tacrolimus
Therapeutics
Dermis
Methotrexate
Skin
Pharmaceutical Preparations

Keywords

  • Localized scleroderma
  • Morphea
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parodi, A. (2015). Morphea (localized scleroderma). In European Handbook of Dermatological Treatments, Third Edition (pp. 637-642). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_64

Morphea (localized scleroderma). / Parodi, Aurora.

European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg, 2015. p. 637-642.

Research output: Chapter in Book/Report/Conference proceedingChapter

Parodi, A 2015, Morphea (localized scleroderma). in European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg, pp. 637-642. https://doi.org/10.1007/978-3-662-45139-7_64
Parodi A. Morphea (localized scleroderma). In European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg. 2015. p. 637-642 https://doi.org/10.1007/978-3-662-45139-7_64
Parodi, Aurora. / Morphea (localized scleroderma). European Handbook of Dermatological Treatments, Third Edition. Springer Berlin Heidelberg, 2015. pp. 637-642
@inbook{b82a84437f3b4360b825482c1864043b,
title = "Morphea (localized scleroderma)",
abstract = "Morphea is a fibrosing disorder of the skin without systemic involvement. It can be clinically classified in different forms: circumscribed, linear, generalized, pansclerotic and mixed forms. The pathogenesis is not completely understood. An underlying predisposition and environmental factors are required to develop the disease. No causal treatment for morphea exists. Topical systemic and phototherapy are used. Topical treatments are adequate for limited forms, while phototherapy and systemic treatment are used for the more severe forms of the disease. Corticosteroids are the mainstay of topical treatments. Topical calcipotriol and tacrolimus have been evaluated in open studies and they seem to improve significantly morphea. UVA1 which penetrate deeper in the dermis than narrow-band UVB are usually considered the best option in phototherapy. Methotrexate is the systemic drug which has the best evidences; it can be used in addition to corticosteroids, in particular in severe morphea of young people.",
keywords = "Localized scleroderma, Morphea, Treatment",
author = "Aurora Parodi",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-662-45139-7_64",
language = "English",
isbn = "9783662451397",
pages = "637--642",
booktitle = "European Handbook of Dermatological Treatments, Third Edition",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Morphea (localized scleroderma)

AU - Parodi, Aurora

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Morphea is a fibrosing disorder of the skin without systemic involvement. It can be clinically classified in different forms: circumscribed, linear, generalized, pansclerotic and mixed forms. The pathogenesis is not completely understood. An underlying predisposition and environmental factors are required to develop the disease. No causal treatment for morphea exists. Topical systemic and phototherapy are used. Topical treatments are adequate for limited forms, while phototherapy and systemic treatment are used for the more severe forms of the disease. Corticosteroids are the mainstay of topical treatments. Topical calcipotriol and tacrolimus have been evaluated in open studies and they seem to improve significantly morphea. UVA1 which penetrate deeper in the dermis than narrow-band UVB are usually considered the best option in phototherapy. Methotrexate is the systemic drug which has the best evidences; it can be used in addition to corticosteroids, in particular in severe morphea of young people.

AB - Morphea is a fibrosing disorder of the skin without systemic involvement. It can be clinically classified in different forms: circumscribed, linear, generalized, pansclerotic and mixed forms. The pathogenesis is not completely understood. An underlying predisposition and environmental factors are required to develop the disease. No causal treatment for morphea exists. Topical systemic and phototherapy are used. Topical treatments are adequate for limited forms, while phototherapy and systemic treatment are used for the more severe forms of the disease. Corticosteroids are the mainstay of topical treatments. Topical calcipotriol and tacrolimus have been evaluated in open studies and they seem to improve significantly morphea. UVA1 which penetrate deeper in the dermis than narrow-band UVB are usually considered the best option in phototherapy. Methotrexate is the systemic drug which has the best evidences; it can be used in addition to corticosteroids, in particular in severe morphea of young people.

KW - Localized scleroderma

KW - Morphea

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84944584889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944584889&partnerID=8YFLogxK

U2 - 10.1007/978-3-662-45139-7_64

DO - 10.1007/978-3-662-45139-7_64

M3 - Chapter

AN - SCOPUS:84944584889

SN - 9783662451397

SN - 9783662451380

SP - 637

EP - 642

BT - European Handbook of Dermatological Treatments, Third Edition

PB - Springer Berlin Heidelberg

ER -